7Camphall AM, Crampette L, Lebal B, et al. In vitro inhibition of PGD2 and LTC4 release from human nasal polyp cells by ebastine and care bastine. Allergy, 1995, 26(suppl 1): 194.
8Eda R, Sugiyama H, Hopp RJ, et al.Effect of loratadine on human eosinephil function in vitro. Ann Allergy,1993, 71: 373.
9Michel L, Dubertret L, Jean- Louis F, et al. Modulation of IgE - dependent hypersensitivity reaction by mizolastine: inhibition of antigen- induced soluble ICAM - 1release. J Invest Dermatol, 1997, 108: 822.
10Lindquist M, Edwards IR.Risk of nonsedating antihistamines. Lancet, 1997, 394: 1322.
4[13]Ko CM,Ducic I, Fan J, et al. Suppression of mammalian K + channelfamily by ebastine[J]. Pharmacol Exp Ther, 1997,281:233～244
5[14]Ducic I,Ko CM,Shuba Y,et al. Comparative effects of loratadine and terfenadine on cardiac K + channels [J]. J Cardiovasc Pharmacol,1997,30:42～54
6[15]Suessbrich H,Waldegger S, Lang F, et al. Blockade of HERC channels expressed in xenopus oocytes by the histamine recepter antagonists terfenadine and astemixole[J]. FEBS, 1996,385: 77～80
7[16]Paserchia LA, Hewett J, Woosley RL, et al. Effect of ketoconazlole on QTc[J]. Clin Pharmacol Ther, 1994,55: 146
8[17]Biton B, Maitre S, Godet D, et al. Effect of the noval nonsedating histamine H1 recepter antagonist mizolastine on cardiac potassium and sodium currents[J]. Allergy, 1998,53: 419
9[18]Leeson GA, Chan KY, Knapp WC, et al. Metabolic disposition of terfenadine in laboratory animals [J]. Arzeimittelforschung, 1982, 32:1173～1178
10[19]Michiels M, Van Peer A, Woestenborghs R, et al. Pharmcokineticsand tissue distribution of astemizole in the dog[J ]. Drug Dev Res,1986,8:53～62
8Lindquist M, Edwards IR. Risks of non - sedating antihistamines[ J]. Lancet, 1997,349 ( 9061 ) : 1322 - 1322.
9Passalacqna G, Bousquet J, Bachert C, et al. The clinical safety of H1 -receptor antagonists. An EAACI position paper [ J]. Allergy, 1996,51 (10) :666 -675.
